SHR-1905 injection for chronic rhinosinusitis with nasal polyps
Tests SHR-1905 injection in adults with chronic rhinosinusitis with nasal polyps.
Key facts
- Who runs it
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 280 people, planned
- Started
- 28 Aug 2025
- Expected to end
- Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- SHR-1905 Injection
- SHR-1905 Placebo Injection
- Record updated
- 17 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic rhinosinusitis with nasal polyps (long-term sinus swelling with growths in the nose). It tests SHR-1905 injection against a placebo (dummy injection).
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Nasal polyps in both nostrils, with a total polyp score (NPS) of at least 5 and at least 2 in each nostril. Nasal blockage score (NCS) of at least 2. SNOT-22 symptom score of at least 30. Symptoms for over 4 weeks before screening. Weight at least 40kg (88 lb (40 kg)).
- Earlier treatment
- Must have had standard nose steroid sprays (INCS). Must have had nasal polyp surgery in the past and/or steroid tablets or injections (SCS) within 1 years before screening, unless these cannot be used. No SCS or extra INCS within 4 weeks before randomisation. No sinus or nose surgery within 6 months before screening.
Main reasons for not taking part
- Immune system weakness, or HIV, active hepatitis B, hepatitis C or syphilis antibodies
- Uncontrolled high blood pressure or uncontrolled diabetes
- Cancer diagnosed within 5 years, except low-risk types
- Lung test FEV1 below 50% before inhaler use
- Pregnancy, breastfeeding, smoking, or quitting smoking less than 6 months ago
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Weight ≥40kg
- Diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP)
- Bilateral nasal polyps at screening and baseline, total NPS ≥5, ≥2 points for each nostril
- NCS ≥2 at screening and baseline
- SNOT-22≥30 at screening period and baseline
- Recorded persistent NP symptoms for over 4 weeks prior to screening
- Subjects received standard therapy with intranasal corticosteroids (INCS) prior to randomization
- NP surgery in the past and/or SCS use within 1 years before screening(or with contraindications/ intolerances)
Who cannot take part
- Concomitant with immunodeficiency
- Concomitant with contraindications or not suitable for nasal endoscopy
- Concomitant with infection within 4 weeks prior to randomization
- Uncontrolled epistaxis within 4 weeks prior to randomization
- Major surgery performed within 3 months prior to randomization, or surgery planned during the study, or treatments that may affect evaluations according to investigators
- Parasitic infection within 6 months before randomization
- Sinus or intranasal surgery within 6 months prior to screening, or changes in the nasal walls caused by sinus or intranasal surgery that made NPS evaluation impossible
- Concomitant with active hepatitis B, positive hepatitis C virus antibodies, positive human immunodeficiency virus antibodies, or positive treponema pallidum antibodies
- Transfusion of blood products or immunoglobulin within 4 weeks prior to randomization
- SCS or additional INCS use within 4 weeks before randomization, or planned use during treatment period
- Regular use of decongestants (local or systemic) within 4 weeks before randomization, except for during the endoscopic procedure
- Adnimistration of live vaccine or viral vector vaccine within 4 weeks before randomization
- Allergen immunotherapy within 8 weeks before randomization
- Substance abuse, drug abuse, and/or excessive alcohol consumption within 1 year prior to randomization; Pregnancy (including positive pregnancy test at screening or baseline), lactation, or pregnancy plan during study period
- Uncontrolled hypertension and/or uncontrolled diabetes
- Malignancies diagnosed within 5 years before randomization (except those with a low risk of metastasis or death)
- Abnormalities of laboratory tests at screening or baseline
- Prolonged QTc interval or other clinically significant abnormal results of ECG at screening or baseline that may cause significant safety risks to subjects
- Any comorbidities that may affect the efficacy evaluation of nasal polyps
- Any comorbidities except for asthma that may affect blood EOS levels
- FEV1 before the use of bronchodilator (pre-BD) was less than 50% at screening
- Smoking at screening, or smoking cessation less than 6 months at screening
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP)
The 2 groups in the trial
- SHR-1905 InjectionTreatment being tested
- SHR-1905 Placebo InjectionPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Efficacy and Safety Study of SHR-1905 in Patiens With Chronic Rhinosinusitis With Nasal Polyps
- Plain-language title
- SHR-1905 injection for chronic rhinosinusitis with nasal polypsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07132827, who can take part
- Record updated
- 17 November 2025